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1 
Drug Utilization and the 
Pharmaceutical Pipeline: 
Correctional Health Care 
Formulary Considerations 
 
 
 
Objectives  
• Overview the drug utilization trends of the top traditional therapy 
classes within the community and assess their impact on drug 
utilization within correctional systems.  
 
• Identify new agents in development and compare them with 
currently available treatment options by therapeutic class as well 
as summarize first time generic dates of availability of commonly 
used agents over the next 24 months. 
 
• Assess the impact of new medications and newly approved 
generic formulations will on correctional health care and their 
formularies  
 
2 
Notes 
• Dr. Hamel does do not have any relevant financial 
relationships with commercial interests nor any 
affiliation with products presented 
• Medications presented in late-phase studies 
• Not an all inclusive review of pharmacy pipeline 
• Generic names are provided and proposed trade 
names when available 
• Actions by FDA cannot be speculated nor inferred 
• Presenter cannot guarantee correct pronunciation of 
generic names in all cases 
3 
Generic Pipeline: Cardiovascular 
Product Name 
Anticipated 
Generic Entry 
2011 US Sales  
(In millions) 
Clopidogrel (Plavix® ) 5/2012 $5,020 
Valsartan (Diovan® 
/Diovan HCT® ) 
9/2012 $1,585/$1,431 
Candesartan (Atacand® 
/Atacand HCT® ) 
12/2012 $95/$46 
Fenofibrate (Tricor®) 1/2013 $1,111 
Niacin (Niaspan®) 9/2013 $954 
http://www.medcohealth.com/art/corporate/anticipatedfirsttime_generics.pdf. Accessed September 25, 2012  
Cardiovascular: Market Trends 
• Cholesterol and hypertension #2 and #3 in traditional 
drug class spend in 2011 
• Market spending expected to decrease 
– HTN and cholesterol generic entry’s  
• JNC 8 and ATP IV expected in 2012 
– Expected broader recommendations for statin use  
• Top Medications by market share 2011: 
– Cholesterol-simvastatin, rosuvastatin, atorvastatin 
– HTN-lisinopril, metoprolol, amlodipine, valsartan 
 
Cardiovascular: Pipeline Trends 
• Continued development on oral anticoagulants with 
improved safety and efficacy over warfarin 
 
• Robust lipid-lowering pipeline–Novel molecule 
investigations as well as reformulations of old stand-
bys 
 
• Approvals may hinge more on safety concerns than 
demonstration of efficacy 
 
• Significant cost saving opportunities with generic 
entries 
 
 
Cardiovascular: Anticoagulant 
Factor Xa inhibitors 
• Orally administered with predictable effect, does not require frequent monitoring  
• Fewer known drug interactions  
– FDA-Approved–Rivaroxaban   (Xarelto ®) 
 
Apixaban (Eliquis®) 
• Prevention of stroke in AF and VTE prevention and treatment, twice daily 
• AVERROES–comparison vs. ASA–50% reduction in stroke and embolism risk 
• ARISTOTLE–comparison vs. warfarin–Superior stroke and embolism prevention 
with lower major bleeding risk 
• CRL in 6/2011. Decision date 3/17/2013 
 
Edoxaban (Lixiana®) 
• Stroke prevention in AF and VTE prevention post surgery, once daily 
• STARS J-V–significant reduction in DVT (↓65%) vs. enoxaparin 
• Ongoing studies 
– ENGAGE-AF TIMI-largest AF study with 21,000 participants 
– HOKUSAI VTE-largest study of VTE with 7,500 participants 
 
 
Cardiovascular: Lipid-Lowering 
Mipomersen (Kynamro®)  
• Apo-B inhibitor dosed weekly as SQ injection 
• LDL and Apo-B reductions demonstrated ~30% added to statin 
• Increase benign and malignant neoplasms noted 
• Review by FDA advisory panel set for 10/2012 and decision by 
1/29/2013 
 
Laropiprant + niacin (Tredaptive™, formerly Cordaptive™)  
• Co-formulated extended-release niacin with laropiprant, novel 
flushing inhibitor 
• D/C due adverse reactions ~10% vs. 22.2% with niacin 
• Non-approvable letter from FDA in 2008, resubmission expected 
2012 following completion of HPS2-THRIVE 
– Cardiac outcomes trial with 25,000 patients 
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Cardiovascular: Lipid Lowering 
Icosapent ethyl (VASCEPA™, formerly AMR101) 
• Prescription grade omega-3 fatty acid for dyslipidemia and very high TG (300-
500 mg/dL) 
• MARINE–20-33% TG reduction in patients with very high TG (already on statin) 
• ANCHOR–10-21% TG reduction dyslipidemia (already on statin) without raising 
LDL 
• FDA approved 7/2012, but still not available on market 
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Generic Pipeline: 
Infectious Disease 
Product Name Anticipated 
Generic Entry 
2011 US Sales  
(In millions) 
Valganciclovir (Valcyte® ) 3/2013 $224 
Moxifloxacin (Avelox®) 2/2014 $376 
Nelfinavir (Viracept®) 4/2014 $44 
Efavirenz (Susteva®) 3/2015 $141 
Ritonavir (Norvir®) 1/2015 $422 
Linezolid (Zyvox®) 5/2015 $271 
http://www.medcohealth.com/art/corporate/anticipatedfirsttime_generics.pdf. Accessed September 25, 2012  
Infectious Disease: Market Trends 
• Increased generic formulations with stagnant pipeline 
– Generic levofloxacin  
– Increased generic options for azithromycin, ciprofloxacin and 
amoxicillin/clavulanate 
• Increased rifaximin utilization 
• Generic entry of lamivudine in 2012 
– Cost savings opportunity in HIV regimens 
• Anticipated generic moxifloxacin (2014) and 
ceftibuten (2014) not expected to impact market 
 
Infectious Disease: Pipeline 
Trends 
• Continued development of novel direct-acting oral 
antivirals for hepatitis C 
– Protease inhibitors and polymerase inhibitors 
 
• Movement toward all oral combination regimens utilizing 
3-4 drug regimens 
 
• Development of new integrase inhibitors for HIV 
 
• New once-daily one-pill combination formulations for 
HIV  
 
 
Infectious Disease: Hepatitis C 
Simeprevir (formerly TMC 435) 
• Once-daily protease inhibitor 12-24 weeks 
• PILLAR-SVR=76-84% in treatment naïve genotype 1 
• Phase II underway with GS-7977 QD polymerase inhibitor and ribavirin 
• 3 Phase III trials currently underway and combo w/ daclatasvir 
• Fast-tracked by FDA July 2011 and global filings expected 1st half 2013 
 
Sofosbuvir (Formerly GS-7977 and PSI-7977)  
• Once-daily polymerase inhibitor 
• Phase II-88% undetectable in treatment naïve (interferon free) 
• Prior null responders, 8/9 patients with undetectable VL relapsed (interferon 
free) 
• Three interferon free phase III trials underway in genotype 1,2,3,4 
• NDA expected in second half 2013 
 
 
Infectious Disease: Hepatitis C 
Faldaprevir (Formerly BI 201335 )  
• Once daily protease inhibitor 12-24 weeks 
• Phase II-Genotype I 
• SILEN-C1=SVR ~84% in treatment naïve with SOC 48 weeks 
• SILEN-C2=SVR~35%(null) + 50% (partial) with SOC 24 weeks 
• SILEN-C3=SVR ~80% and 82% in treatment naïve with SOC (12 and 24 weeks) 
• Phase III SOUND-C2 5-arm study with IFN free regimen with RBV and 
polymerase inhibitor-Interim results--38%-68% SVR 
• Fast-tracked April 2011 (SOC and INF-free) and launch expected 2014 
 
Daclatasvir (Formerly BMS 790052)   
• Once daily NS5A inhibitor given 12-24 weeks with SOC 
• Phase II–SVR~83% in treatment naïve genotype 1 vs. 25% placebo 
• Phase III-COMMAND-3 daclatasvir vs telaprevir  (+ifn/rbv) 
• Phase III in treatment naïve patients co-infected HIV  
Infectious Disease: HIV 
Dolutegravir (GSK-1349572) 
• Oral, once-daily, unboosted, integrase inhibitor 
• Continued activity in raltegravir-resistant strains (Q148) 
• SPRING II–88% undectable VL vs. 85% with raltegrevir  
• SINGLE–88% undectable VL vs. 81% with tenofovir/emtricitabine/efavirenz  
• Combination product with abacavir/lamivudine (572-Trii) 
• Filing expected end of 2012 
 
GS-7340  
• Prodrug of tenofovir 
• Higher potency and lower median effective concentration compared to 
tenofovir 
• Dosed 10 times lower than tenofovir 
• Intracellular concentrations ~4-33x greater but blood concentrations lower than tenofovir 
• Combination product with darunavir, cobicistat, FTC 
 
 
HIV: human immunodeficiency virus 
Generic Pipeline  
Central Nervous System (CNS): 
Product Name Anticipated 
Generic Entry 
2011 US Sales  
(In millions) 
Duloxetine (Cymbalta® ) 12/2013 $2.891 
Aripiprazole (Abilify®) 4/2015 $4,077 
Quetiapine (Seroquel XR®) 6/2016 $1,003 
http://www.medcohealth.com/art/corporate/anticipatedfirsttime_generics.pdf. Accessed September 25, 2012  
CNS: Market Trends 
• Generic entry of olanzapine, quetiapine and 
ziprasidone expected to have large impact  
– Despite availability brand use still increasing 
– Aripiprazole largest cost driver 
 
• New atypical antipsychotics aim to reduce 
unfavorable side effect 
 
• Top Medications by market share 2011: 
– Mental Health-Quetiapine, aripiprazole, 
donezepril, risperdone 
CNS: Antipsychotics 
Loxapine (Adasuve Staccato®) 
• Inhaled, typical antipsychotic 
• Rapid treatment of agitation in patients with schizophrenia or bipolar 
disorder (onset~10 minutes) 
• 08/2010 and 05/2012 FDA issued CRL  
• Re-filing expected 12/2012 
 
Bitopertin  (Formerly RG1678) 
• First in class glycine reuptake inhibitor (GRI) 
• Adjunct for negative symptoms in schizophrenia and suboptimally 
controlled symptoms 
• Phase III trials initiated in early 2011 
 
• Filing anticipated in 2014 
 
 
 
CNS: 
Antipsychotics/Antidepressants 
Cariprazine (RGH-188)  
• Atypical antipsychotic, D3/D2 antagonist for schizophrenia, bipolar II and 
MDD 
• Low potency on 5-HTC2, H1, muscarinic, and adrenergic receptors 
• Phase III-Significant improvement in symptoms in acute manic episodes 
vs. placebo 
• Filing anticipated in 2012 
 
 
 
 
Generic Pipeline:  
Pain Management 
Product Name Anticipated 
Generic Entry 
2011 US Sales  
(In millions) 
Lidocaine (Lidoderm® ) 11/2012 $1,125 
Oxymorphone (Opana ER® ) 1/2013 $405 
Duloxetine (Cymbalta® ) 12/2013 $3,434 
Celcoxib (Celebrex® ) 5/2014 $1,497 
http://www.medcohealth.com/art/corporate/anticipatedfirsttime_generics.pdf. Accessed September 25, 2012 
Pain Management: Market Trends 
• US accounts for 80% of worldwide Rx opioid use 
• Pain management products focus on abuse 
deterrence 
– New products available-Opana ER, Oxycontin 
– Older formulations removed from market 
• 2011 FDA requirement to reduce APAP content to 
325 mg in combination products within 3 years 
• Top Medications by market share 2011: 
– Pain-Hydrocodone/APAP, oxycodone/apap, 
tramadol, amitriptyline, oxycodone 
CNS: Pain Management 
• Little in the development of new molecular 
entities 
• Increase in reformulated pain products 
– New Combinations 
– New Controlled-Release Matrix 
– New Routes of Administration 
– Abuse Deterring Agents 
• Strategy–Up-armor, Gel, Antagonize, Punish 
 
Pain Management 
• New/Reformulations (Phase III-Preregistration) 
• Tamper Resistance/Abuse Deterrence 
• Oxycodone ER (Remoxy®) 
• Oxycodone IR (Acurox®) 
• Hydrocodone ER(CEP-33237) 
 
• Extended/Immediate Release 
• Hydrocodone (Zohydro SODAS®) 
 
• Combinations 
• Morphine/oxycodone (MoxDuo® IR and CR) 
Pain Management 
• New Routes of Administration 
• Fentanyl sublingual spray (Subsys®) 
• Morphine nasal spray (RylomineTM) 
• Cannabidiol/tetrahydocannabinol oral spray 
(Sativex®) 
• Intranasal ketamine (EreskaTM) 
• Buprenorphine SC implant (Probuphine) 
• Oral transmucosal buprenorphine BEMA® 
• Dihydroergotamine (Levadex) inhaler 
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Generic Pipeline:  
Respiratory 
Product Name Anticipated 
Generic Entry 
2011 US Sales  
(In millions) 
Levalbuterol (Xopenex®)* 8/2012 $415 
Montelukast (Singulair®) 8/2012 $4,420 
Sildenafil (Revatio® ) 9/2012 $180 
Mometasone (Nasonex® ) 7/2014 $1,122 
Ipratropium/Albuterol 
(Combivent® ) 
12/2015 $889 
http://www.medcohealth.com/art/corporate/anticipatedfirsttime_generics.pdf. Accessed September 25, 2012  
* Not HFA formulation 
Respiratory: Market Trends  
• Community market expected to grow ~30% in 
next 3-4 years 
– Inhaled steroids market driver 
– New combination ICS/LABA inhalers 
• Generic entry of leukotriene inhibitors 
• Generic versions of current inhaled steroids and 
combination inhalers?????? 
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Respiratory: Pipeline Trends 
• Strong pipeline for COPD compared to asthma 
 
• New long-acting antimuscarinic agents (LAMA) and 
long-acting beta agonists (LABA) 
 
• New combination inhalers with shift toward LAMA + 
LABA 
 
• New inhaler devices–security concerns 
 
• Generic versions of current inhaled steroids? 
 
 
Respiratory: Combination Products  
 
 
 Class Agents Indication 
Long-acting muscarinic 
antagonist and Long-acting 
beta agonist  
GSK573719/Vilanterol 
Tiotropium/Olodaterol 
Glycopyrronium /Indacaterol 
Aclidinium /Formoterol 
COPD 
Long-acting beta agonist 
and inhaled steroid 
Fluticasone/Vilanterol  COPD and Asthma 
Respiratory  
Aclidinium (Tudorza Pressair ®) 
• Twice daily long-acting antimuscarinic agent for COPD 
• Lower systemic exposure vs. tiotropium 
• Combination formulation with formoterol in development 
• NDA filed July 2011, FDA approved 7/2012  
 
 
Glycopyrronium (Seebri ®)   
• Once daily long-acting antimuscarinic agent for COPD 
• Development of combination formulation with indacaterol 
• NDA filed in 2011, FDA response requesting additional  
 clinical data 
 
 
 
Respiratory  
Fluticasone/vilanterol (Breo®) 
• Once daily LABA with inhaled steroid for COPD and asthma  
• Phase III-Significant FEV1 improvement vs. placebo and fluticasone 
monotherapy, but not vilanterol monotherapy 
• Large16,000 patient COPD study currently underway   
• NDA filed 7/2012. Response expected 05/12/2013 
 
Glycopyrronium/Indacaterol   
• Once daily LAMA/LABA for COPD 
• ILLUMINATE-phase III vs. salmeterol/fluticasone. Greater FEV1 after 12 
hours 
• SHINE-phase III vs. monotherapy tiotropium, glycopyrronium and 
indacaterol. Significantly greater FEV1 after 12 hours vs. monotherapies 
• US filing anticipated end of 2014 
 
 
 
Generic Pipeline:  
Diabetes 
Product Name Anticipated 
Generic Entry 
2011 US Sales  
(In millions) 
Rosiglitazone (Avandia®) 3/2012 $286 
Rosiglitazone/Metformin 
(Avandamet®) 
3/2012 $161 
Rosiglitazone/Glimepiride 
(Avandaryl®) 
3/2012 $35 
Pioglitazone (Actos®) 8/2012 $2,830 
Pioglitazone/glimepiride 
(Duetact®) 
12/2012 $31 
Pioglitazone/metformin (Actos 
Met®) 
12/2012 $426 
http://www.medcohealth.com/art/corporate/anticipatedfirsttime_generics.pdf. Accessed September 25, 2012  
Diabetes: Market Trends  
• Top Traditional Drug Class in 2011 
– Highest per member/month spend 
– ~10% of traditional market 
• GLP-1 and DPP-4 inhibitors driving spending 
• Metformin use still increasing 
• Sharp decreases in TZD utilization 
• Top Medications by market share: 
– Metformin, Insulin glargine ,pioglitazone, glipizide 
34 
Diabetes: GLP-1 Analogs  
Albiglutide (Syncria®) 
• Once weekly GLP-1 analog  
• Fuses human GLP-1 analog with human albumin 
• Current recruitment evaluating usefulness in heart failure 
 
Dulaglutide  
• Once weekly GLP-1 analog  
• Phase III studies 
• Dulaglutide vs. insulin glargine (6/2015) 
• Dulaglutide vs once-daily liraglutide (6/2014) 
• Filing expected 4th quarter 2012 
 
Lixisenatide (Lyxumia®) 
• Once weekly GLP-1 analog  
• Additional ~0.8-0.9 HgbA1c when added on to metformin 
• Filling anticipated in 4th quarter 2012  
 
 
 
Diabetes: Insulins 
Inhaled Insulin (Afrezza ®) 
• Inhaled insulin with ultra rapid acting onset (~10 minutes) 
• Comparable HgbA1c reduction to insulin aspart and insulin lispro 
• Two different inhaler devices utilized in clinical trials 
• 1/2011 FDA 2nd Complete Response Letter requesting 2 additional trials 
• 8/2011 Design confirmed for requested trials  
      results expected 2013 
Degludec   (Tresiba ®) 
• Ultra long-acting insulin (duration ~40 hours), Once daily or 3x weekly 
dosing 
• Comparable HgbA1c reduction to insulin glargine with lower overall and 
nocturnal rates hypoglycemia 
• Combination product with insulin aspart (Novolog®) 
• NDA filed 9/2011. FDA advisory panel set for 11/8/2012 
 
 
 
 
Diabetes: Sodium Glucose Co-
Transporter 2 Inhibitors (SGLT2) 
 
Dapagliflozin  (FORXIGA®) 
• Once daily SGLT2 inhibitor indicated as add-on therapy 
• Additional HgbA1c reduction -0.32%  vs. -0.14% SU add-on 
• Weight loss ~3.7 kg after 24 months vs. +1.36 kg with SU add-on 
• 07/2011-FDA panel concerns surrounding bladder and breast cancer risk 
• 01/2012-CRL from FDA requesting benefit-risk assessment 
 
Canagliflozin 
• Once daily SGLT2 inhibitor as add on 
• HgbA1c reduction -0.93%  vs. -0.81% (glimepiride) as met add-on 
• HgbA1c reduction of 0.65%-0.73% as add-on to insulin 
• HgbA1c additional reduction -0.37%  vs. sitagliptin as add-on to met/SU 
• NDA submitted 5/2012 
 
 
 
 
Trends 
• Middle of “Patent Cliff”−Several “blockbuster” medications 
lost patent protection 
~Estimate $30 Billion 2012 
• Significant new molecule developments in cardiovascular, 
hepatitis C, and central nervous system 
• Stagnant oral antibiotic pipeline   
• Strong COPD pipeline 
• Reformulations of existing molecules for pain management 
to be more tamper resistant 
 
Questions 
Erik Hamel, Pharm.D, BCPS 
333 South St 
Shrewsbury MA 01545 
Tel # 774-455-3310 
Erik.Hamel@umassmed.edu 
 
 
